Despite extensive studies on CD4 1 CD25 1 regulatory T cells (Tregs) during the past decade, the progress on their clinical translation remains stagnant. Mounting evidence suggests that naturally occurring CD8 1 CD122 1 T cells are also Tregs with the capacity to inhibit T-cell responses and suppress autoimmunity as well as alloimmunity. In fact, they are memory-like Tregs that resemble a central memory T cell (T CM ) phenotype. The mechanisms underlying their suppression are still not well understood, although they may include IL-10 production. We have recently demonstrated that programmed death-1 (PD-1) expression distinguishes between regulatory and memory CD8 1 CD122 1 T cells and that CD8
INTRODUCTION
Regulatory T cells (Tregs) are essential for maintaining immune tolerance by regulating both autoimmunity and alloimmunity. In addition to CD4 1 CD251 Tregs, CD8
1 Tregs are emerging as an important subset of T suppressors. Since the original reports showing that CD8 1 T cells also possess Treg properties, [1] [2] [3] tremendous progress in understanding their suppression of immune responses has been made. Liu et al. 4 have demonstrated the specific suppression of T helper activity by CD8
1

CD28
2 T cells. The same cells also reportedly induced CD4 1 T-cell anergy 5 and regulated reactivation of T and NKT cells. 6 Furthermore, antigen-induced CD8
1
CD103
1 Tregs have been shown to suppress effector T-cell function 7 and to be significantly increased in spontaneously tolerant recipients of liver allografts. 8 It has also been reported that Qa-1-restricted CD8 1 T cells regulate the activation of T cells as well as NKT cells.
6 Therefore, CD8 24, 25 They carry a surface marker, CD25 (IL-2 receptor a), with specific intracellular expression of FoxP3. [24] [25] [26] They are also CD44 high with some nonspecific cell surface markers such as glucocorticoid-induced TNF receptor. 27 In contrast, CD8 31 Therefore, further studies are needed to draw a conclusion regarding the role of the CXCR3 marker in defining the
1 T cells have been traditionally described as antigen-specific memory T cells. [21] [22] [23] In particular, the phenotype of CD8 1 CD122 1 Tregs generally resemble a central memory T cell phenotype. Are they true memory, regulatory or memory-like Tregs? Given their essential and opposing roles in long-term immunity versus immune tolerance, it is important to reconcile this dichotomy. These questions of fundamental immunology are too important to be ignored.
It has been reported that PD-1 expression on CD8 1 T cells is responsible for their exhaustion during chronic viral infection and that PD-1 blockade restores their function. [32] [33] [34] [35] Moreover, previous studies have shown that homeostatically proliferated T cells contain PD-1 1 and PD-1 2 fractions and that the PD-1 1 subset of the cells are dysfunctional. 36 We have sought to determine if naturally occurring CD8 
CD122
1 Tregs. 18 We have found that antigen-specific CD8
2 cells are true memory T cells that respond to a previously encountered antigen other than a specific donor antigen. However, they could also play an unwanted regulatory role in tumor immunity. Wang et al. 15 found that removal of CD8
1
CD122
1 Tregs resulted in a greater expansion of tumor-specific T cells and tumor infiltration of functional effector/memory T cells. They demonstrated that the proliferation of CD8
1
CD122
1 Tregs in reconstituted, lymphodepleted mice limited the antitumor efficacy of DC vaccination in conjunction with adoptive transfer of tumor-specific T cells. Simultaneous inhibition of CD4
1
CD25
1 and CD8
Tregs by blocking CTLA-4 and PD-L1 protected T-cell activation from their regulation and enhanced antitumor immunity, 43 implying that CD8 
CD122
1 Tregs regulate not only autoimmunity but also alloimmunity and tumor immunity, suggesting a broad involvement of CD8
1
CD122
1 Tregs in immune regulation.
ANTIGEN-SPECIFICITY OF CD8
1 CD122 1 TREGS It remains unclear whether the suppression by naturally arising CD8 1 CD122 1 Tregs is antigen-specific. A recent study by Okuno et al. 38 has demonstrated that CD8 1 CD122 1 Tregs contain clonally expanded cell populations with identical CDR3 sequences of the T-cell receptor b-chain, suggesting that they may specifically recognize certain antigens via their TCRb-chain. We have previously shown that 'bystander' memory CD8
1 T cells with a central memory T cell (T CM ) phenotype suppress allograft rejection. 37 We also have found that the suppressive capacity of CD8 
CD122
1 T cells are Tregs in various animal models of diseases, their mechanisms of action are not well understood. As shown in Figure 2 , IL-10 produced by CD8 
1 Tregs appears to be a main mechanism responsible for their suppression.
10,18,44 Endharti et al. 10 presented the first data showing that CD8
1
CD122
1 Tregs suppressed IFN-c production and proliferation of CD8 1 T cells by producing IL-10 in vitro.
10
The CD8 1 Tregs also recognized activated T cells via the interaction of MHC class I-ab TCR and regulated target T cells by producing IL-10. 44 We also found that suppression of allograft rejection by IL-10-deficient CD8
1
CD122
1 Tregs was significantly reduced. 18 However, IL-10 did not account for all mechanisms underlying CD8 1
1 Treg suppression.
18
Other mechanisms, in addition to IL-10 production, could be involved in their suppression. In particular, CD8
Tregs also released IFN-c and TGF-b, which suppress CD4 1 T-cell activation. 17 It remains to be defined if CTL activities generated by CD8
1
CD122
1 Tregs are also involved in regulating effector T cells. Despite previous findings, more studies will be needed to fully understand the mechanisms underlying their suppression of immune responses.
FUNCTIONAL REQUIREMENT FOR CD8
1 CD122 1 TREG-MEDIATED SUPPRESSION Many previous studies have shown that the B7/CD28 costimulatory pathway is essential for the homeostasis of CD4 1 CD25 1 FoxP3 1 Tregs, 45 while IL-2 is also critical for their development and function. 46 However, the functional requirement of costimulatory pathways and cytokines for CD8 1 CD122 1 Tregs is not clear. Shi et al. 12 reported that B7/CD28 costimulatory blockade by antibodies or using CD28-deficient CD8 1 CD122 1 Tregs abrogated their suppressive activity, indicating that they exert their suppression via the B7/CD28 interaction that is essential for them to produce suppressive cytokines, such as IL-10. We have recently shown that the presence of both the B7/CD28 costimulatory and PD-L1/ PD-1 co-inhibitory pathways is required for their optimal production of IL-10, 18 suggesting that they do need some costimulatory signaling to acquire their suppressive function by producing IL-10. However, IL-2 could be involved in the generation and function of CD8 
CD122
1 Tregs were much more effective in the suppression of allograft rejection and underwent faster homeostatic proliferation than CD4 1 CD251 Tregs. 20 Moreover, they produced more IL-10 and were more potent in the suppression of in vitro T-cell proliferation than CD4 
CD25
1 Tregs and conventional effector T cells, resulting in an unaltered immune balance, whereas administering IL-15 enhanced the expansion and function of CD8
1
CD122
1 Tregs, but not effector T cells. Therefore, cell therapies of allograft rejection using CD8
1
CD122
1 Tregs appear to be promising. Our findings may help find remedies for the cure of autoimmune diseases or allograft rejection.
CONCLUSIONS
Naturally occurring CD8
1
CD122
1 T cells clearly display immunoregulatory properties that inhibit T-cell responses and suppress autoimmunity as well as alloimmunity. They are memorylike Tregs, resembling a T CM phenotype, while PD-1 serves as a critical biomarker that can distinguish between memory and regulatory CD8
1
CD122
1 T cells. The mechanisms underlying their suppression mainly include IL-10 production and possible CTL-mediated killing of activated T cells. More studies are warranted to fully understand their mechanisms of action. We have recently demonstrated that CD8
1
CD122
1 Tregs, in addition to conventional CD4
1
CD25
1 Tregs, are another choice for suppressing allograft rejection. Could they represent a better therapeutic approach than CD4
1
CD25
1 Tregs? Further studies from independent groups are needed to draw a definite conclusion on whether CD8
1
CD122
1 Tregs are more effective in suppression than conventional CD4 1 CD251 Tregs. Our findings could lay the groundwork for clinical trials using CD8
1
CD122
1 Treg therapies and may lead to new strategies for the cure of human autoimmune diseases or allograft rejection.
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